Cancer Stem Cells as a Predictive Factor in Radiotherapy

Seminars in Radiation Oncology

Volumn 22, Issue 2, 2012, Pages 151-174

  Brunner, Thomas B ^a   Kunz Schughart, Leoni A ^b   Grosse Gehling, Philipp ^b   Baumann, Michael ^b,c  

^a UNIVERSITY OF OXFORD   (United Kingdom)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED LEUKOCYTE CELL ADHESION MOLECULE; ALDEHYDE DEHYDROGENASE; CD133 ANTIGEN; CD147 ANTIGEN; CD24 ANTIGEN; CD44V ANTIGEN; CD44V6 ANTIGEN; CHEMOKINE RECEPTOR CXCR4; HERMES ANTIGEN; STROMAL CELL DERIVED FACTOR 1;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER STEM CELL; CELL SURVIVAL; COLORECTAL CANCER; CYTOTOXICITY; DNA REPAIR; GLIOBLASTOMA; HEAD AND NECK CANCER; HEMATOLOGY; HUMAN; METASTASIS; NONHUMAN; PANCREAS CANCER; PH; PRIMARY TUMOR; PRIORITY JOURNAL; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RADIOSENSITIVITY; REVIEW; SOLID TUMOR; TUMOR CELL; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME; TUMOR XENOGRAFT;

HUMANS; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; NEOPLASTIC STEM CELLS; TUMOR MARKERS, BIOLOGICAL; TUMOR MICROENVIRONMENT;

EID: 84857611290     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2011.12.003     Document Type: Review

References (309)

1. Holthusen H. Erfahrungen über die Verträglichkeitsgrenze für Röntgenstrahlen und deren Nutzanwendung zur Verhütung von Schäden. Strahlentherapie 1936, 57:254-269.
2. Hill R.P., Milas L. The proportion of stem cells in murine tumors. Int J Radiat Oncol Biol Phys 1989, 16:513-518.
3. Zielske S.P., Spalding A.C., Wicha M.S., et al. Ablation of breast cancer stem cells with radiation. Transl Oncol 2011, 4:227-233.
4. Desgrandchamps F. Recurrence following radiotherapy. Front Radiat Ther Oncol 2008, 41:86-92.
5. Singh S.K., Hawkins C., Clarke I.D., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
6. Bao S., Wu Q., McLendon R.E., et al. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760.
7. Prince M.E., Sivanandan R., Kaczorowski A., et al. Identification of a subpopulation of cells with cancer stem cell properties in head and neck squamous cell carcinoma. Proc Natl Acad Sci U S A 2007, 104:973-978.
8. Yu F., Yao H., Zhu P., et al. Let-7 regulates self renewal and tumorigenicity of breast cancer cells. Cell 2007, 131:1109-1123.
9. Al-Hajj M., Wicha M.S., Benito-Hernandez A., et al. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A 2003, 100:3983-3988.
10. Ginestier C., Hur M.H., Charafe-Jauffret E., et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567.
11. Eramo A., Lotti F., Sette G., et al. Identification and expansion of the tumorigenic lung cancer stem cell population. Cell Death Differ 2008, 15:504-514.
12. Huang D., Gao Q., Guo L., et al. Isolation and identification of cancer stem-like cells in esophageal carcinoma cell lines. Stem Cells Dev 2009, 18:465-473.
13. Zhao J.S., Li W.J., Ge D., et al. Tumor initiating cells in esophageal squamous cell carcinomas express high levels of CD44. PLoS One 2011, 6:e21419.
14. + cancer stem cells in human liver cancer. Cancer Cell 2008, 13:153-166.
15. Hermann P.C., Huber S.L., Herrler T., et al. Distinct populations of cancer stem cells determine tumor growth and metastatic activity in human pancreatic cancer. Cell Stem Cell 2007, 1:313-323.
16. Li C., Heidt D.G., Dalerba P., et al. Identification of pancreatic cancer stem cells. Cancer Res 2007, 67:1030-1037.
17. Yang Y.M., Chang J.W. Bladder cancer initiating cells (BCICs) are among EMA-CD44v6+ subset: Novel methods for isolating undetermined cancer stem (initiating) cells. Cancer Invest 2008, 26:725-733.
18. Feng D., Peng C., Li C., et al. Identification and characterization of cancer stem-like cells from primary carcinoma of the cervix uteri. Oncol Rep 2009, 22:1129-1134.
19. Yao T., Chen Q., Lin Z., et al. The expression of ALDH1 in cervical carcinoma. Med Sci Monit 2011, 17:HY21-HY26.
20. O'Brien C.A., Pollett A., Gallinger S., et al. A human colon cancer cell capable of initiating tumour growth in immunodeficient mice. Nature 2007, 445:106-110.
21. Ricci-Vitiani L., Lombardi D.G., Pilozzi E., et al. Identification and expansion of human colon-cancer-initiating cells. Nature 2007, 445:111-115.
22. Dalerba P., Dylla S.J., Park I.K., et al. Phenotypic characterization of human colorectal cancer stem cells. Proc Natl Acad Sci U S A 2007, 104:10158-10163.
23. Collins A.T., Berry P.A., Hyde C., et al. Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 2005, 65:10946-10951.
24. Schatton T., Murphy G.F., Frank N.Y., et al. Identification of cells initiating human melanomas. Nature 2008, 451:345-349.
25. Beier C.P., Beier D. CD133 negative cancer stem cells in glioblastoma. Front Biosci (Elite Ed) 2011, 3:701-710.
26. Campos B., Herold-Mende C.C. Insight into the complex regulation of CD133 in glioma. Int J Cancer 2011, 128:501-510.
27. Looney W.B., Hopkins H.A. Rationale for different chemotherapeutic and radiation therapy strategies in cancer management. Cancer 1991, 67:1471-1483.
28. Baumann M., Krause M., Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 2008, 8:545-554.
29. Gurtner K., Deuse Y., Bütof R., et al. Diverse effects of combined radiotherapy and EGFR inhibition with antibodies or TK inhibitors on local tumour control and correlation with EGFR gene expression. Radiother Oncol 2011, 99:323-330.
30. Baumann M., Krause M., Zips D., et al. Selective inhibition of the epidermal growth factor tyrosine kinase by BIBX1382BS improves growth delay but not local control after fractionated irradiation in human FaDu squamous cell carcinoma in nude mice. Int J Radiat Biol 2003, 79:547-559.
31. Krause M., Hessel F., Zips D., et al. Adjuvant inhibition of the epidermal growth factor receptor after fractionated irradiation of FaDu human squamous cell carcinoma. Radiother Oncol 2004, 72:95-101.
32. Zips D., Hessel F., Krause M., et al. Impact of adjuvant inhibition of vascular endothelial growth factor receptor tyrosine kinases on tumor growth delay and local tumor control after fractionated irradiation in human squamous cell carcinomas in nude mice. Int J Radiat Oncol Biol Phys 2005, 61:908-914.
33. Weppler S.A., Krause M., Zyromska A., et al. Response of U87 glioma xenografts treated with concurrent rapamycin and fractionated radiotherapy: Possible role for thrombosis. Radiother Oncol 2007, 82:96-104.
34. Zips D., Le K., Yaromina A., et al. Triple angiokinase inhibition, tumour hypoxia and radiation response of FaDu human squamous cell carcinomas. Radiother Oncol 2009, 92:405-410.
35. Seymour C.B., Mothersill C. Lethal mutations, the survival curve shoulder and split-dose recovery. Int J Radiat Biol 1989, 56:999-1010.
36. Baumann M., Krause M., Thames H., et al. Cancer stem cells and radiotherapy. Int J Radiat Biol 2009, 85:391-402.
37. Trott K.R. Relation between division delay and damage expressed in later generations. Curr Top Radiat Res Q 1972, 7:336-337.
38. Banasiak D., Barnetson A.R., Odell R.A., et al. Comparison between the clonogenic, MTT, and SRB assays for determining radiosensitivity in a panel of human bladder cancer cell lines and a ureteral cell line. Radiat Oncol Investig 1999, 7:77-85.
39. Clarke M.F., Dick J.E., Dirks P.B., et al. Cancer stem cells-Perspectives on current status and future directions: AACR workshop on cancer stem cells. Cancer Res 2006, 66:9339-9344.
40. Fαbiαn A., Barok M., Vereb G., et al. Die hard: Are cancer stem cells the Bruce Willises of tumor biology?. Cytometry A 2009, 75:67-74.
41. Gupta P.B., Chaffer C.L., Weinberg R.A. Cancer stem cells: Mirage or reality?. Nat Med 2009, 15:1010-1012.
42. Koch U., Krause M., Baumann M. Cancer stem cells at the crossroads of current cancer therapy failures-Radiation oncology perspective. Semin Cancer Biol 2010, 20:116-124.
43. Maenhaut C., Dumont J.E., Roger P.P., et al. Cancer stem cells: A reality, a myth, a fuzzy concept or a misnomer?. An analysis. Carcinogenesis 2010, 31:149-158.
44. Rahman M., Deleyrolle L., Vedam-Mai V., et al. The cancer stem cell hypothesis: Failures and pitfalls. Neurosurgery 2011, 68:531-545. discussion 545.
45. Sengupta A., Cancelas J.A. Cancer stem cells: A stride towards cancer cure?. J Cell Physiol 2010, 225:7-14.
46. Tomasson M.H. Cancer stem cells: A guide for skeptics. J Cell Biochem 2009, 106:745-749.
47. Bomken S., Fiser K., Heidenreich O., et al. Understanding the cancer stem cell. Br J Cancer 2010, 103:439-445.
48. Crowe D.L., Parsa B., Sinha U.K. Relationships between stem cells and cancer stem cells. Histol Histopathol 2004, 19:505-509.
49. McDonald S.A., Graham T.A., Schier S., et al. Stem cells and solid cancers. Virchows Arch 2009, 455:1-13.
50. Wicha M.S., Liu S., Dontu G. Cancer stem cells: An old idea-A paradigm shift. Cancer Res 2006, 66:1883-1890. discussion 1895-1896.
51. Lluis F., Cosma M.P. Cell-fusion-mediated somatic-cell reprogramming: A mechanism for tissue regeneration. J Cell Physiol 2010, 223:6-13.
52. Dittmar T., Nagler C., Schwitalla S., et al. Recurrence cancer stem cells-Made by cell fusion?. Med Hypotheses 2009, 73:542-547.
53. Lu X., Kang Y. Cell fusion as a hidden force in tumor progression. Cancer Res 2009, 69:8536-8539.
54. Lu X., Kang Y. Cell fusion hypothesis of the cancer stem cell. Adv Exp Med Biol 2011, 714:129-140.
55. Nagler C., Zänker K.S., Dittmar T. Cell fusion, drug resistance and recurrence CSCs. Adv Exp Med Biol 2011, 714:173-182.
56. Singh S.K., Clarke I.D., Terasaki M., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003, 63:5821-5828.
57. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: Accumulating evidence and unresolved questions. Nat Rev Cancer 2008, 8:755-768.
58. Chen L., Shen R., Ye Y., et al. Precancerous stem cells have the potential for both benign and malignant differentiation. PLoS One 2007, 2:e293.
59. Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell 2011, 144:646-674.
60. Tysnes B.B. Tumor-initiating and -propagating cells: Cells that we would like to identify and control. Neoplasia 2010, 12:506-515.
61. Quintana E., Shackleton M., Sabel M.S., et al. Efficient tumour formation by single human melanoma cells. Nature 2008, 456:593-598.
62. Shackleton M., Quintana E. Progress in understanding melanoma propagation. Mol Oncol 2010, 4:451-457.
63. Suit H.D., Sedlacek R.S., Zietman A. Quantitative transplantation assays of spontaneous tumors of the C3H mouse as allografts in athymic NCr/Sed-nu/nu nude mice and isografts in C3Hf/Sed mice. Cancer Res 1988, 48:4525-4528.
64. Zietman A.L., Suit H.D., Ramsay J.R., et al. Quantitative studies on the transplantability of murine and human tumors into the brain and subcutaneous tissues of NCr/Sed nude mice. Cancer Res 1988, 48:6510-6516.
65. Taghian A., Budach W., Zietman A., et al. Quantitative comparison between the transplantability of human and murine tumors into the subcutaneous tissue of NCr/Sed-nu/nu nude and severe combined immunodeficient mice. Cancer Res 1993, 53:5012-5017.
66. Taghian A., Budach W., Zietman A., et al. Quantitative comparison between the transplantability of human and murine tumors into the brain of NCr/Sed-nu/nu nude and severe combined immunodeficient mice. Cancer Res 1993, 53:5018-5021.
67. Huang P., Taghian A., Allam A., et al. The effect of whole-body irradiation of nude mice on the tumor transplantability and control probability of a human soft tissue sarcoma xenograft. Radiat Res 1996, 145:337-342.
68. Baumann M., Krause M. CD44: A cancer stem cell-related biomarker with predictive potential for radiotherapy. Clin Cancer Res 2010, 16:5091-5093.
69. Baiocchi M., Biffoni M., Ricci-Vitiani L., et al. New models for cancer research: Human cancer stem cell xenografts. Curr Opin Pharmacol 2010, 10:380-384.
70. Alison M.R., Lim S.M., Nicholson L.J. Cancer stem cells: Problems for therapy?. J Pathol 2011, 223:147-161.
71. Somervaille T.C., Cleary M.L. Identification and characterization of leukemia stem cells in murine MLL-AF9 acute myeloid leukemia. Cancer Cell 2006, 10:257-268.
72. Heuser M., Humphries R.K. Biologic and experimental variation of measured cancer stem cells. Cell Cycle 2010, 9:909-912.
73. Zhang M., Behbod F., Atkinson R.L., et al. Identification of tumor-initiating cells in a p53-null mouse model of breast cancer. Cancer Res 2008, 68:4674-4682.
74. Cho R.W., Wang X., Diehn M., et al. Isolation and molecular characterization of cancer stem cells in MMTV-Wnt-1 murine breast tumors. Stem Cells 2008, 26:364-371.
75. Read T.A., Fogarty M.P., Markant S.L., et al. Identification of CD15 as a marker for tumor-propagating cells in a mouse model of medulloblastoma. Cancer Cell 2009, 15:135-147.
76. Wang J., Wakeman T.P., Lathia J.D., et al. Notch promotes radioresistance of glioma stem cells. Stem Cells 2010, 28:17-28.
77. Pastrana E., Silva-Vargas V., Doetsch F. Eyes wide open: A critical review of sphere-formation as an assay for stem cells. Cell Stem Cell 2011, 8:486-498.
78. Galli R., Binda E., Orfanelli U., et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res 2004, 64:7011-7021.
79. Yuan X., Curtin J., Xiong Y., et al. Isolation of cancer stem cells from adult glioblastoma multiforme. Oncogene 2004, 23:9392-9400.
80. Kalluri R., Weinberg R.A. The basics of epithelial-mesenchymal transition. J Clin Invest 2009, 119:1420-1428.
81. Laks D.R., Masterman-Smith M., Visnyei K., et al. Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells 2009, 27:980-987.
82. Wang J., Sakariassen P.Ø., Tsinkalovsky O., et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 2008, 122:761-768.
83. Günther H.S., Schmidt N.O., Phillips H.S., et al. Glioblastoma-derived stem cell-enriched cultures form distinct subgroups according to molecular and phenotypic criteria. Oncogene 2008, 27:2897-2909.
84. Hansford L.M., McKee A.E., Zhang L., et al. Neuroblastoma cells isolated from bone marrow metastases contain a naturally enriched tumor-initiating cell. Cancer Res 2007, 67:11234-11243.
85. Bao S., Wu Q., Sathornsumetee S., et al. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 2006, 66:7843-7848.
86. Zhang Q.B., Ji X.Y., Huang Q., et al. Differentiation profile of brain tumor stem cells: A comparative study with neural stem cells. Cell Res 2006, 16:909-915.
87. Stratford A.L., Reipas K., Maxwell C., et al. Targeting tumour-initiating cells to improve the cure rates for triple-negative breast cancer. Expert Rev Mol Med 2010, 12:e22.
88. Wicha M.S. Cancer stem cell heterogeneity in hereditary breast cancer. Breast Cancer Res 2008, 10:105.
89. Grimshaw M.J., Cooper L., Papazisis K., et al. Mammosphere culture of metastatic breast cancer cells enriches for tumorigenic breast cancer cells. Breast Cancer Res 2008, 10:R52.
90. Ponti D., Costa A., Zaffaroni N., et al. Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 2005, 65:5506-5511.
91. Kreso A, O'Brien CA: Colon cancer stem cells. Curr Protoc Stem Cell 7:3.1.1-3.1.12., 2008.
92. Vermeulen L., Todaro M., de Sousa Mello F., et al. Single-cell cloning of colon cancer stem cells reveals a multi-lineage differentiation capacity. Proc Natl Acad Sci U S A 2008, 105:13427-13432.
93. Todaro M., Francipane M.G., Medema J.P., et al. Colon cancer stem cells: Promise of targeted therapy. Gastroenterology 2010, 138:2151-2162.
94. Du L., Wang H., He L., et al. CD44 is of functional importance for colorectal cancer stem cells. Clin Cancer Res 2008, 14:6751-6760.
95. Luk S.U., Lee T.K., Liu J., et al. Chemopreventive effect of PSP through targeting of prostate cancer stem cell-like population. PLoS One 2011, 6:e19804.
96. Tesei A., Zoli W., Arienti C., et al. Isolation of stem/progenitor cells from normal lung tissue of adult humans. Cell Prolif 2009, 42:298-308.
97. Lim Y.C., Oh S.Y., Cha Y.Y., et al. Cancer stem cell traits in squamospheres derived from primary head and neck squamous cell carcinomas. Oral Oncol 2011, 47:83-91.
98. Schatton T., Frank M.H. The in vitro spheroid melanoma cell culture assay: Cues on tumor initiation?. J Invest Dermatol 2011, 130:1769-1771.
99. Wan F., Zhang S., Xie R., et al. The utility and limitations of neurosphere assay, CD133 immunophenotyping and side population assay in glioma stem cell research. Brain Pathol 2010, 20:877-889.
100. Pollard S.M., Yoshikawa K., Clarke I.D., et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell 2009, 4:568-580.
101. Woolard K., Fine H.A. Glioma stem cells: Better flat than round. Cell Stem Cell 2009, 4:466-467.
102. Pandita A., Aldape K.D., Zadeh G., et al. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. Genes Chromosomes Cancer 2004, 39:29-36.
103. De Witt Hamer P.C., Van Tilborg A.A., Eijk P.P., et al. The genomic profile of human malignant glioma is altered early in primary cell culture and preserved in spheroids. Oncogene 2008, 27:2091-2096.
104. Vescovi A.L., Galli R., Reynolds B.A. Brain tumour stem cells. Nat Rev Cancer 2006, 6:425-436.
105. Sasai K., Romer J.T., Lee Y., et al. Shh pathway activity is down-regulated in cultured medulloblastoma cells: Implications for preclinical studies. Cancer Res 2006, 66:4215-4222.
106. Dangles-Marie V., Pocard M., Richon S., et al. Establishment of human colon cancer cell lines from fresh tumors versus xenografts: Comparison of success rate and cell line features. Cancer Res 2007, 67:398-407.
107. Daniel V.C., Marchionni L., Hierman J.S., et al. A primary xenograft model of small-cell lung cancer reveals irreversible changes in gene expression imposed by culture in vitro. Cancer Res 2009, 69:3364-3373.
108. Garber K. From human to mouse and back: "Tumorgraft" models surge in popularity. J Natl Cancer Inst 2009, 101:6-8.
109. Beier D., Hau P., Proescholdt M., et al. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 2007, 67:4010-4015.
110. Al-Assar O., Muschel R.J., Mantoni T.S., et al. Radiation response of cancer stem-like cells from established human cell lines after sorting for surface markers. Int J Radiat Oncol Biol Phys 2009, 75:1216-1225.
111. Yeung T.M., Gandhi S.C., Wilding J.L., et al. Cancer stem cells from colorectal cancer-derived cell lines. Proc Natl Acad Sci U S A 2010, 107:3722-3727.
112. Dittfeld C., Dietrich A., Peickert S., et al. CD133 expression is not selective for tumor-initiating or radioresistant cell populations in the CRC cell line HCT-116. Radiother Oncol 2010, 94:375-383.
113. Milas L., Hittelman W.N. Cancer stem cells and tumor response to therapy: Current problems and future prospects. Semin Radiat Oncol 2009, 19:96-105.
114. Hirschhaeuser F., Menne H., Dittfeld C., et al. Multicellular tumor spheroids: An underestimated tool is catching up again. J Biotechnol 2010, 148:3-15.
115. Todaro M., Perez Alea M., Scopelliti A., et al. IL-4-mediated drug resistance in colon cancer stem cells. Cell Cycle 2008, 7:309-313.
116. Kemper K., Grandela C., Medema J.P. Molecular identification and targeting of colorectal cancer stem cells. Oncotarget 2010, 1:387-395.
117. Zöller M. CD44: Can a cancer-initiating cell profit from an abundantly expressed molecule?. Nat Rev Cancer 2011, 11:254-267.
118. Alison M.R., Islam S., Wright N.A. Stem cells in cancer: Instigators and propagators?. J Cell Sci 2010, 123:2357-2368.
119. - metastatic colon cancer cells initiate tumors. J Clin Invest 2008, 118:2111-2120.
120. Wu Y., Wu P.Y. CD133 as a marker for cancer stem cells: Progresses and concerns. Stem Cells Dev 2009, 18:1127-1134.
121. LaBarge M.A., Bissell M.J. Is CD133 a marker of metastatic colon cancer stem cells?. J Clin Invest 2008, 118:2021-2024.
122. Navarro-Alvarez N., Kondo E., Kawamoto H., et al. Isolation and propagation of a human CD133(-) colon tumor-derived cell line with tumorigenic and angiogenic properties. Cell Transplant 2010, 19:865-877.
123. Neuzil J., Stantic M., Zobalova R., et al. Tumour-initiating cells vs. cancer "stem" cells and CD133: What's in the name?. Biochem Biophys Res Commun 2007, 355:855-859.
124. Hermann P.C., Bhaskar S., Cioffi M., et al. Cancer stem cells in solid tumors. Semin Cancer Biol 2010, 20:77-84.
125. Kemper K., Sprick M.R., de Bree M., et al. The AC133 epitope, but not the CD133 protein, is lost upon cancer stem cell differentiation. Cancer Res 2010, 70:719-729.
126. Taïeb N., Maresca M., Guo X.J., et al. The first extracellular domain of the tumour stem cell marker CD133 contains an antigenic ganglioside-binding motif. Cancer Lett 2009, 278:164-173.
127. Horst D., Kriegl L., Engel J., et al. CD133 expression is an independent prognostic marker for low survival in colorectal cancer. Br J Cancer 2008, 99:1285-1289.
128. Horst D., Scheel S.K., Liebmann S., et al. The cancer stem cell marker CD133 has high prognostic impact but unknown functional relevance for the metastasis of human colon cancer. J Pathol 2009, 219:427-434.
129. Takahashi S., Kamiyama T., Tomaru U., et al. Frequency and pattern of expression of the stem cell marker CD133 have strong prognostic effect on the surgical outcome of colorectal cancer patients. Oncol Rep 2010, 24:1201-1212.
130. Saigusa S., Tanaka K., Toiyama Y., et al. Immunohistochemical features of CD133 expression: Association with resistance to chemoradiotherapy in rectal cancer. Oncol Rep 2010, 24:345-350.
131. Yasuda H., Tanaka K., Saigusa S., et al. Elevated CD133, but not VEGF or EGFR, as a predictive marker of distant recurrence after preoperative chemoradiotherapy in rectal cancer. Oncol Rep 2009, 22:709-717.
132. Saigusa S., Tanaka K., Toiyama Y., et al. Clinical significance of CD133 and hypoxia inducible factor-1alpha gene expression in rectal cancer after preoperative chemoradiotherapy. Clin Oncol (R Coll Radiol) 2011, 23:323-332.
133. Sagiv E., Arber N. The novel oncogene CD24 and its arising role in the carcinogenesis of the GI tract: From research to therapy. Expert Rev Gastroenterol Hepatol 2008, 2:125-133.
134. Kristiansen G., Sammar M., Altevogt P. Tumour biological aspects of CD24, a mucin-like adhesion molecule. J Mol Histol 2004, 35:255-262.
135. Schabath H., Runz S., Joumaa S., et al. CD24 affects CXCR4 function in pre-B lymphocytes and breast carcinoma cells. J Cell Sci 2006, 119:314-325.
136. Sagiv E., Memeo L., Karin A., et al. CD24 is a new oncogene, early at the multistep process of colorectal cancer carcinogenesis. Gastroenterology 2006, 131:630-639.
137. Sagiv E., Starr A., Rozovski U., et al. Targeting CD24 for treatment of colorectal and pancreatic cancer by monoclonal antibodies or small interfering RNA. Cancer Res 2008, 68:2803-2812.
138. Lathia J.D., Gallagher J., Heddleston J.M., et al. Integrin alpha 6 regulates glioblastoma stem cells. Cell Stem Cell 2010, 6:421-432.
139. Mulholland D.J., Xin L., Morim A., et al. Lin-Sca-1+CD49fhigh stem/progenitors are tumor-initiating cells in the Pten-null prostate cancer model. Cancer Res 2009, 69:8555-8562.
140. Jo M., Eastman B.M., Webb D.L., et al. Cell signaling by urokinase-type plasminogen activator receptor induces stem cell-like properties in breast cancer cells. Cancer Res 2010, 70:8948-8958.
141. Robertson J.H., Yang S.Y., Winslet M.C., et al. Functional blocking of specific integrins inhibit colonic cancer migration. Clin Exp Metastasis 2009, 26:769-780.
142. Pawar S.C., Dougherty S., Pennington M.E., et al. alpha6 integrin cleavage: Sensitizing human prostate cancer to ionizing radiation. Int J Radiat Biol 2007, 83:761-767.
143. Cordes N., Park C.C. beta1 integrin as a molecular therapeutic target. Int J Radiat Biol 2007, 83:753-760.
144. Patel B.B., Yu Y., Du J., et al. Age-related increase in colorectal cancer stem cells in macroscopically normal mucosa of patients with adenomas: A risk factor for colon cancer. Biochem Biophys Res Commun 2009, 378:344-347.
145. Dalerba P., Cho R.W., Clarke M.F. Cancer stem cells: Models and concepts. Annu Review Med 2007, 58:267-284.
146. Weichert W., Knösel T., Bellach J., et al. ALCAM/CD166 is overexpressed in colorectal carcinoma and correlates with shortened patient survival. J Clin Pathol 2004, 57:1160-1164.
147. Lugli A., Iezzi G., Hostettler I., et al. Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44s, EpCAM, and ALDH1 in colorectal cancer. Br J Cancer 2010, 103:382-390.
148. de Jong M.C., Pramana J., van der Wal J.E., et al. CD44 expression predicts local recurrence after radiotherapy in larynx cancer. Clin Cancer Res 2010, 16:5329-5338.
149. Gerweck L.E., Zaidi S.T., Zietman A. Multivariate determinants of radiocurability. I: Prediction of single fraction tumor control doses. Int J Radiat Oncol Biol Phys 1994, 29:57-66.
150. Konstantopoulos K., Thomas S.N. Cancer cells in transit: The vascular interactions of tumor cells. Annu Rev Biomed Eng 2009, 11:177-202.
151. Jung T., Castellana D., Klingbeil P., et al. CD44v6 dependence of premetastatic niche preparation by exosomes. Neoplasia 2009, 11:1093-1105.
152. Desai B., Ma T., Zhu J., et al. Characterization of the expression of variant and standard CD44 in prostate cancer cells: Identification of the possible molecular mechanism of CD44/MMP9 complex formation on the cell surface. J Cell Biochem 2009, 108:272-284.
153. Coppola D., Hyacinthe M., Fu L., et al. CD44V6 expression in human colorectal carcinoma. Hum Pathol 1998, 29:627-635.
154. Weg-Remers S., Anders M., von Lampe B., et al. Decreased expression of CD44 splicing variants in advanced colorectal carcinomas. Eur J Cancer 1998, 34:1607-1611.
155. Mulder J.W., Kruyt P.M., Sewnath M., et al. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet 1994, 344:1470-1472.
156. Wielenga V.J., van der Voort R., Mulder J.W., et al. CD44 splice variants as prognostic markers in colorectal cancer. Scand J Gastroenterol 1998, 33:82-87.
157. Morrin M., Delaney P.V. CD44v6 is not relevant in colorectal tumour progression. Int J Colorectal Dis 2002, 17:30-36.
158. Ngan C.Y., Yamamoto H., Seshimo I., et al. A multivariate analysis of adhesion molecules expression in assessment of colorectal cancer. J Surg Oncol 2007, 95:652-662.
159. Choi D., Lee H.W., Hur K.Y., et al. Cancer stem cell markers CD133 and CD24 correlate with invasiveness and differentiation in colorectal adenocarcinoma. World J Gastroenterol 2009, 15:2258-2264.
160. Huh J.W., Kim H.R., Kim Y.J., et al. Expression of standard CD44 in human colorectal carcinoma: Association with prognosis. Pathol Int 2009, 59:241-246.
161. Adamia S., Maxwell C.A., Pilarski L.M. Hyaluronan and hyaluronan synthases: Potential therapeutic targets in cancer. Curr Drug Targets Cardiovasc Haematol Disord 2005, 5:3-14.
162. Ponta H., Sherman L., Herrlich P.A. CD44: From adhesion molecules to signalling regulators. Nat Rev Mol Cell Biol 2003, 4:33-45.
163. Naor D., Wallach-Dayan S.B., Zahalka M.A., et al. Involvement of CD44, a molecule with a thousand faces, in cancer dissemination. Semin Cancer Biol 2008, 18:260-267.
164. Toole B.P. Hyaluronan-CD44 interactions in cancer: Paradoxes and possibilities. Clin Cancer Res 2009, 15:7462-7468.
165. Morrison H., Sperka T., Manent J., et al. Merlin/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac. Cancer Res 2007, 67:520-527.
166. Kim Y., Lee Y.S., Choe J., et al. CD44-epidermal growth factor receptor interaction mediates hyaluronic acid-promoted cell motility by activating protein kinase C signaling involving Akt, Rac1, Phox, reactive oxygen species, focal adhesion kinase, and MMP-2. J Biol Chem 2008, 283:22513-22528.
167. Wang S.J., Bourguignon L.Y. Hyaluronan and the interaction between CD44 and epidermal growth factor receptor in oncogenic signaling and chemotherapy resistance in head and neck cancer. Arch Otolaryngol Head Neck Surg 2006, 132:771-778.
168. Baumann M., Krause M., Dikomey E., et al. EGFR-targeted anti-cancer drugs in radiotherapy: Preclinical evaluation of mechanisms. Radiother Oncol 2007, 83:238-248.
169. Toole B.P., Slomiany M.G. Hyaluronan, CD44 and Emmprin: Partners in cancer cell chemoresistance. Drug Resist Updat 2008, 11:110-121.
170. Zhou S., Schuetz J.D., Bunting K.D., et al. The ABC transporter Bcrp1/ABCG2 is expressed in a wide variety of stem cells and is a molecular determinant of the side-population phenotype. Nat Med 2001, 7:1028-1034.
171. Goodell M.A., Brose K., Paradis G., et al. Isolation and functional properties of murine hematopoietic stem cells that are replicating in vivo. J Exp Med 1996, 183:1797-1806.
172. Goodell M.A., Rosenzweig M., Kim H., et al. Dye efflux studies suggest that hematopoietic stem cells expressing low or undetectable levels of CD34 antigen exist in multiple species. Nat Med 1997, 3:1337-1345.
173. Kondo T., Setoguchi T., Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci U S A 2004, 101:781-786.
174. Harris M.A., Yang H., Low B.E., et al. Cancer stem cells are enriched in the side population cells in a mouse model of glioma. Cancer Res 2008, 68:10051-10059.
175. Wu C., Alman B.A. Side population cells in human cancers. Cancer Lett 2008, 268:1-9.
176. Bleau A.M., Hambardzumyan D., Ozawa T., et al. PTEN/PI3K/Akt pathway regulates the side population phenotype and ABCG2 activity in glioma tumor stem-like cells. Cell Stem Cell 2009, 4:226-235.
177. Bleau A.M., Huse J.T., Holland E.C. The ABCG2 resistance network of glioblastoma. Cell Cycle 2009, 8:2936-2944.
178. Loebinger M.R., Giangreco A., Groot K.R., et al. Squamous cell cancers contain a side population of stem-like cells that are made chemosensitive by ABC transporter blockade. Br J Cancer 2008, 98:380-387.
179. Misra S., Heldin P., Hascall V.C., et al. Hyaluronan-CD44 interactions as potential targets for cancer therapy. FEBS J 2011, 278:1429-1443.
180. Efferth T., Langguth P. Transport processes of radiopharmaceuticals and -modulators. Radiol Oncol 2011, 6:59.
181. Slomiany M.G., Grass G.D., Robertson A.D., et al. Hyaluronan, CD44, and emmprin regulate lactate efflux and membrane localization of monocarboxylate transporters in human breast carcinoma cells. Cancer Res 2009, 69:1293-1301.
182. Sattler U.G., Mueller-Klieser W. The anti-oxidant capacity of tumour glycolysis. Int J Radiat Biol 2009, 85:963-971.
183. Walenta S., Mueller-Klieser W.F. Lactate: Mirror and motor of tumor malignancy. Semin Radiat Oncol 2004, 14:267-274.
184. Dimmer K.S., Friedrich B., Lang F., et al. The low-affinity monocarboxylate transporter MCT4 is adapted to the export of lactate in highly glycolytic cells. Biochem J 2000, 350:219-227.
185. Sonveaux P., Végran F., Schroeder T., et al. Targeting lactate-fueled respiration selectively kills hypoxic tumor cells in mice. J Clin Invest 2008, 118:3930-3942.
186. Ullah M.S., Davies A.J., Halestrap A.P. The plasma membrane lactate transporter MCT4, but not MCT1, is up-regulated by hypoxia through a HIF-1alpha-dependent mechanism. J Biol Chem 2006, 281:9030-9037.
187. Quennet V., Yaromina A., Zips D., et al. Tumor lactate content predicts for response to fractionated irradiation of human squamous cell carcinomas in nude mice. Radiother Oncol 2006, 81:130-135.
188. Sattler U.G., Meyer S.S., Quennet V., et al. Glycolytic metabolism and tumour response to fractionated irradiation. Radiother Oncol 2010, 94:102-109.
189. Yaromina A., Quennet V., Zips D., et al. Co-localisation of hypoxia and perfusion markers with parameters of glucose metabolism in human squamous cell carcinoma (hSCC) xenografts. Int J Radiat Biol 2009, 85:972-980.
190. Hjelmeland A.B., Wu Q., Heddleston J.M., et al. Acidic stress promotes a glioma stem cell phenotype. Cell Death Differ 2011, 18:829-840.
191. Brizel D.M., Schroeder T., Scher R.L., et al. Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001, 51:349-353.
192. Walenta S., Chau T.V., Schroeder T., et al. Metabolic classification of human rectal adenocarcinomas: A novel guideline for clinical oncologists?. J Cancer Res Clin Oncol 2003, 129:321-326.
193. Walenta S., Doetsch J., Mueller-Klieser W., et al. Metabolic imaging in multicellular spheroids of oncogene-transfected fibroblasts. J Histochem Cytochem 2000, 48:509-522.
194. Baumann F., Leukel P., Doerfelt A., et al. Lactate promotes glioma migration by TGF-beta2 dependent regulation of matrix metalloproteinase-2. Neuro Oncol 2009, 11:368-380.
195. Goetze K., Walenta S., Ksiazkiewicz M., et al. Lactate enhances motility of tumor cells and inhibits monocyte migration and cytokine release. Int J Oncol 2011, 39:453-463.
196. Ma I., Allan A.L. The role of human aldehyde dehydrogenase in normal and cancer stem cells. Stem Cell Res 2011, 7:292-306.
197. Jackson B., Brocker C., Thompson D.C., et al. Update on the aldehyde dehydrogenase gene (ALDH) superfamily. Hum Genomics 2011, 5:283-303.
198. Storms R.W., Trujillo A.P., Springer J.B., et al. Isolation of primitive human hematopoietic progenitors on the basis of aldehyde dehydrogenase activity. Proc Natl Acad Sci U S A 1999, 96:9118-9123.
199. Alison M.R., Guppy N.J., Lim S.M., et al. Finding cancer stem cells: Are aldehyde dehydrogenases fit for purpose?. J Pathol 2010, 222:335-344.
200. Douville J., Beaulieu R., Balicki D. ALDH1 as a functional marker of cancer stem and progenitor cells. Stem Cells Dev 2009, 18:17-25.
201. Croker AK, Allan AL: Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDH(hi)CD44 (+) human breast cancer cells. Breast Cancer Res Treat (in press).
202. Scadden D.T. The stem-cell niche as an entity of action. Nature 2006, 441:1075-1079.
203. Jang Y.Y., Sharkis S.J. Stem cell plasticity: A rare cell, not a rare event. Stem. Cell Res 2005, 1:45-51.
204. Li L., Neaves W.B. Normal stem cells and cancer stem cells: The niche matters. Cancer Res 2006, 66:4553-4557.
205. Iwasaki H., Suda T. Cancer stem cells and their niche. Cancer Sci 2009, 100:1166-1172.
206. Burness M.L., Sipkins D.A. The stem cell niche in health and malignancy. Semin Cancer Biol 2010, 20:107-115.
207. Borovski T., De Sousa E Melo F., Vermeulen L., et al. Cancer stem cell niche: The place to be. Cancer Res 2011, 71:634-639.
208. Lathia J.D., Heddleston J.M., Venere M., et al. Deadly teamwork: Neural cancer stem cells and the tumor microenvironment. Cell Stem Cell 2011, 8:482-485.
209. Cruz M., Siden Å., Tasat D.R., et al. Are all glioma cells cancer stem cells?. J Cancer Sci Ther 2010, 2:100-106.
210. Charles N.A., Holland E.C. TRRAP and the maintenance of stemness in gliomas. Cell Stem Cell 2010, 6:6-7.
211. Charles N.A., Holland E.C., Gilbertson R., et al. The brain tumor microenvironment. Glia 2011, 59:1169-1180.
212. Calabrese C., Poppleton H., Kocak M., et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11:69-82.
213. Hambardzumyan D., Becher O.J., Rosenblum M.K., et al. PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev 2008, 22:436-448.
214. Keith B., Simon M.C. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007, 129:465-472.
215. Mohyeldin A., Garzón-Muvdi T., Quiñones-Hinojosa A. Oxygen in stem cell biology: A critical component of the stem cell niche. Cell Stem Cell 2010, 7:150-161.
216. Lin Q., Yun Z. Impact of the hypoxic tumor microenvironment on the regulation of cancer stem cell characteristics. Cancer Biol Ther 2010, 9:949-956.
217. Yaromina A., Thames H., Zhou X., et al. Radiobiological hypoxia, histological parameters of tumour microenvironment and local tumour control after fractionated irradiation. Radiother Oncol 2010, 96:116-122.
218. Hambardzumyan D., Squatrito M., Holland E.C., et al. Radiation resistance and stem-like cells in brain tumors. Cancer Cell 2006, 10:454-456.
219. + sector is enlarged by hypoxia. Int J Radiat Oncol Biol Phys 2007, 67:1-5.
220. Platet N., Liu S.Y., Atifi M.E., et al. Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. Cancer Lett 2007, 258:286-290.
221. Seidel S., Garvalov B.K., Wirta V., et al. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain 2010, 133:983-995.
222. Heddleston J.M., Hitomi M., Venere M., et al. Glioma stem cell maintenance: The role of the microenvironment. Curr Pharm Des 2011, 17:2386-2401.
223. Heddleston J.M., Li Z., Lathia J.D., et al. Hypoxia inducible factors in cancer stem cells. Br J Cancer 2010, 102:789-795.
224. Heddleston J.M., Li Z., McLendon R.E., et al. The hypoxic microenvironment maintains glioblastoma stem cells and promotes reprogramming towards a cancer stem cell phenotype. Cell Cycle 2009, 8:3274-3284.
225. Bertout J.A., Majmundar A.J., Gordan J.D., et al. HIF2alpha inhibition promotes p53 pathway activity, tumor cell death, and radiation responses. Proc Natl Acad Sci U S A 2009, 106:14391-14396.
226. Gordan J.D., Bertout J.A., Hu C.J., et al. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 2007, 11:335-347.
227. Franovic A., Holterman C.E., Payette J., et al. Human cancers converge at the HIF-2alpha oncogenic axis. Proc Natl Acad Sci U S A 2009, 106:21306-21311.
228. Tatum J.L., Kelloff G.J., Gillies R.J., et al. Hypoxia: Importance in tumor biology, noninvasive measurement by imaging, and value of its measurement in the management of cancer therapy. Int J Radiat Biol 2006, 82:699-757.
229. Vaupel P. Tumor microenvironmental physiology and its implications for radiation oncology. Semin Radiat Oncol 2004, 14:198-206.
230. Vaupel P. The role of hypoxia-induced factors in tumor progression. Oncologist 2004, 9(suppl 5):10-17.
231. Vaupel P. Hypoxia and aggressive tumor phenotype: Implications for therapy and prognosis. Oncologist 2008, 13(suppl 3):21-26.
232. Vaupel P., Mayer A. Hypoxia in cancer: Significance and impact on clinical outcome. Cancer Metastasis Rev 2007, 26:225-239.
233. Vaupel P., Mayer A., Höckel M. Tumor hypoxia and malignant progression. Methods Enzymol 2004, 381:335-354.
234. Quintana E., Shackleton M., Foster H.R., et al. Phenotypic heterogeneity among tumorigenic melanoma cells from patients that is reversible and not hierarchically organized. Cancer Cell 2010, 18:510-523.
235. Roesch A., Fukunaga-Kalabis M., Schmidt E.C., et al. A temporarily distinct subpopulation of slow-cycling melanoma cells is required for continuous tumor growth. Cell 2010, 141:583-594.
236. Hoek K.S., Goding C.R. Cancer stem cells versus phenotype-switching in melanoma. Pigment cell Melanoma Res 2010, 23:746-759.
237. Scheel C., Weinberg R.A. Phenotypic plasticity and epithelial-mesenchymal transitions in cancer-And normal stem cells?. Int J Cancer 2011, 129:2310-2314.
238. Kong D., Li Y., Wang Z., et al. Cancer stem cells and epithelial-to-mesenchymal transition (EMT)-phenotypic cells: Are they cousins or twins?. Cancers (Basel) 2011, 3:716-729.
239. Floor S., van Staveren W.C., Larsimont D., et al. Cancer cells in epithelial-to-mesenchymal transition and tumor-propagating-cancer stem cells: Distinct, overlapping or same populations. Oncogene 2011, 30:4609-4621.
240. Kucia M., Reca R., Miekus K., et al. Trafficking of normal stem cells and metastasis of cancer stem cells involve similar mechanisms: Pivotal role of the SDF-1-CXCR4 axis. Stem Cells 2005, 23:879-894.
241. Teicher B.A., Fricker S.P. CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 2010, 16:2927-2931.
242. Furusato B., Mohamed A., Uhlén M., et al. CXCR4 and cancer. Pathol Int 2010, 60:497-505.
243. Mueller M.T., Hermann P.C., Heeschen C. Cancer stem cells as new therapeutic target to prevent tumour progression and metastasis. Front Biosci (Elite Ed) 2010, 2:602-613.
244. Croker A.K., Allan A.L. Cancer stem cells: Implications for the progression and treatment of metastatic disease. J Cell Mol Med 2008, 12:374-390.
245. LaBarge M.A., Nelson C.M., Villadsen R., et al. Human mammary progenitor cell fate decisions are products of interactions with combinatorial microenvironments. Integr Biol (Camb) 2009, 1:70-79.
246. Schieke S.M., Ma M., Cao L., et al. Mitochondrial metabolism modulates differentiation and teratoma formation capacity in mouse embryonic stem cells. J Biol Chem 2008, 283:28506-28512.
247. Smolkovα K., Plecitα-Hlavatα L., Bellance N., et al. Waves of gene regulation suppress and then restore oxidative phosphorylation in cancer cells. Int J Biochem Cell Biol 2011, 43:950-968.
248. Jose C., Bellance N., Rossignol R. Choosing between glycolysis and oxidative phosphorylation: A tumor's dilemma?. Biochim Biophys Acta 2011, 1807:552-561.
249. Moreno-Sαnchez R., Rodríguez-Enríquez S., Marín-Hernαndez A., et al. Energy metabolism in tumor cells. FEBS J 2007, 274:1393-1418.
250. Isidoro C., Biagioni F., Giorgi F.S., et al. The role of autophagy on the survival of dopamine neurons. Curr Top Med Chem 2009, 9:869-879.
251. Berridge M.V., Herst P.M., Tan A.S. Metabolic flexibility and cell hierarchy in metastatic cancer. Mitochondrion 2010, 10:584-588.
252. Bjerkvig R., Johansson M., Miletic H., et al. Cancer stem cells and angiogenesis. Semin Cancer Biol 2009, 19:279-284.
253. Bonuccelli G., Tsirigos A., Whitaker-Menezes D., et al. Ketones and lactate "fuel" tumor growth and metastasis: Evidence that epithelial cancer cells use oxidative mitochondrial metabolism. Cell Cycle 2010, 9:3506-3514.
254. Karnoub A.E., Weinberg R.A. Chemokine networks and breast cancer metastasis. Breast Dis 2006, 26:75-85.
255. Brabletz T., Jung A., Reu S., et al. Variable beta-catenin expression in colorectal cancers indicates a tumor progression driven by the tumor environment. Proc Natl Acad Sci U S A 2001, 98:10356-10361.
256. Hlubek F., Brabletz T., Budczies J., et al. Heterogeneous expression of Wnt/beta-catenin target genes within colorectal cancer. Int J Cancer 2007, 121:1941-1948.
257. Mani S.A., Guo W., Liao M.J., et al. The epithelial-mesenchymal transition generates cells with properties of stem cells. Cell 2008, 133:704-715.
258. Morel A.P., Lièvre M., Thomas C., et al. Generation of breast cancer stem cells through epithelial-mesenchymal transition. PLoS One 2008, 3:e2888.
259. Brabletz T., Jung A., Spaderna S., et al. Opinion: Migrating cancer stem cells-an integrated concept of malignant tumour progression. Nat Rev Cancer 2005, 5:744-749.
260. Brabletz S., Bajdak K., Meidhof S., et al. The ZEB1/miR-200 feedback loop controls Notch signalling in cancer cells. EMBO J 2011, 30:770-782.
261. Brabletz S., Brabletz T. The ZEB/miR-200 feedback loop-A motor of cellular plasticity in development and cancer?. EMBO Rep 2010, 11:670-677.
262. Schmalhofer O., Brabletz S., Brabletz T. E-cadherin, beta-catenin, and ZEB1 in malignant progression of cancer. Cancer Metastasis Rev 2009, 28:151-166.
263. Gregory P.A., Bracken C.P., Bert A.G., et al. MicroRNAs as regulators of epithelial-mesenchymal transition. Cell Cycle 2008, 7:3112-3118.
264. Theys J., Jutten B., Habets R., et al. E-cadherin loss associated with EMT promotes radioresistance in human tumor cells. Radiother Oncol 2011, 99:392-397.
265. Du Z., Qin R., Wei C., et al. Pancreatic cancer cells resistant to chemoradiotherapy rich in "stem-cell-like" tumor cells. Dig Dis Sci 2011, 56:741-750.
266. Santisteban M., Reiman J.M., Asiedu M.K., et al. Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res 2009, 69:2887-2895.
267. Kim K.J., Lee K.H., Kim H.S., et al. The presence of stem cell marker-expressing cells is not prognostically significant in glioblastomas. Neuropathology 2011, 31:494-505.
268. + glioblastoma stem-like cells are radiosensitive with a defective DNA damage response compared with established cell lines. Clin Cancer Res 2009, 15:5145-5153.
269. + breast cancer-initiating cells to radiation. J Natl Cancer Inst 2006, 98:1777-1785.
270. Woodward W.A., Chen M.S., Behbod F., et al. WNT/beta-catenin mediates radiation resistance of mouse mammary progenitor cells. Proc Natl Acad Sci U S A 2007, 104:618-623.
271. Al-Assar O., Mantoni T., Lunardi S., et al. Breast cancer stem-like cells show dominant homologous recombination due to a larger S-G2 fraction. Cancer Biol Ther 2011, 11:1028-1035.
272. Lagadec C., Vlashi E., Della Donna L., et al. Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment. Breast Cancer Res 2010, 12:R13.
273. Boivin A., Hanot M., Malesys C., et al. Transient alteration of cellular redox buffering before irradiation triggers apoptosis in head and neck carcinoma stem and non-stem cells. PLoS One 2011, 6:e14558.
274. Vlashi E., Kim K., Lagadec C., et al. In vivo imaging, tracking, and targeting of cancer stem cells. J Natl Cancer Inst 2009, 101:350-359.
275. Saigusa S., Tanaka K., Toiyama Y., et al. Correlation of CD133, OCT4, and SOX2 in rectal cancer and their association with distant recurrence after chemoradiotherapy. Ann Surg Oncol 2009, 16:3488-3498.
276. Du Z., Qin R., Wei C., et al. Pancreatic cancer cells resistant to chemoradiotherapy rich in "stem-cell-like" tumor cells. Dig Dis Sci 2011, 56:741-750.
277. Chen M.S., Woodward W.A., Behbod F., et al. Wnt/beta-catenin mediates radiation resistance of Sca1+ progenitors in an immortalized mammary gland cell line. J Cell Sci 2007, 120:468-477.
278. Brown J.M., Attardi L.D. The role of apoptosis in cancer development and treatment response. Nat Rev Cancer 2005, 5:231-237.
279. Lomonaco S.L., Finniss S., Xiang C., et al. The induction of autophagy by gamma-radiation contributes to the radioresistance of glioma stem cells. Int J Cancer 2009, 125:717-722.
280. Apel A., Herr I., Schwarz H., et al. Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. Cancer Res 2008, 68:1485-1494.
281. Chaachouay H., Ohneseit P., Toulany M., et al. Autophagy contributes to resistance of tumor cells to ionizing radiation. Radiother Oncol 2011, 99:287-292.
282. Rouschop K.M., van den Beucken T., Dubois L., et al. The unfolded protein response protects human tumor cells during hypoxia through regulation of the autophagy genes MAP1LC3B and ATG5. J Clin Invest 2010, 120:127-141.
283. Zhuang W., Li B., Long L., et al. Induction of autophagy promotes differentiation of glioma-initiating cells and their radiosensitivity. Int J Cancer 2011, 129:2720-2731.
284. Zhuang W., Li B., Long L., et al. Knockdown of the DNA-dependent protein kinase catalytic subunit radiosensitizes glioma-initiating cells by inducing autophagy. Brain Res 2011, 1371:7-15.
285. Helgason G.V., Karvela M., Holyoake T.L. Kill one bird with two stones: Potential efficacy of BCR-ABL and autophagy inhibition in CML. Blood 2011, 118:2035-2043.
286. Dewaele M., Maes H., Agostinis P. ROS-mediated mechanisms of autophagy stimulation and their relevance in cancer therapy. Autophagy 2010, 6:838-854.
287. Diehn M., Cho R.W., Lobo N.A., et al. Association of reactive oxygen species levels and radioresistance in cancer stem cells. Nature 2009, 458:780-783.
288. Prevo R., Deutsch E., Sampson O., et al. Class I PI3 kinase inhibition by the pyridinylfuranopyrimidine inhibitor PI-103 enhances tumor radiosensitivity. Cancer Res 2008, 68:5915-5923.
289. Taneja N., Davis M., Choy J.S., et al. Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy. J Biol Chem 2004, 279:2273-2280.
290. Olive P.L. Detection of DNA damage in individual cells by analysis of histone H2AX phosphorylation. Methods Cell Biol 2004, 75:355-373.
291. Diehn M., Clarke M.F. Cancer stem cells and radiotherapy: New insights into tumor radioresistance. J Natl Cancer Inst 2006, 98:1755-1757.
292. Zhang M., Atkinson R.L., Rosen J.M. Selective targeting of radiation-resistant tumor-initiating cells. Proc Natl Acad Sci U S A 2010, 107:3522-3527.
293. Ropolo M., Daga A., Griffero F., et al. Comparative analysis of DNA repair in stem and nonstem glioma cell cultures. Mol Cancer Res 2009, 7:383-392.
294. Charafe-Jauffret E., Ginestier C., Iovino F., et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009, 69:1302-1313.
295. Yilmaz O.H., Valdez R., Theisen B.K., et al. Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 2006, 441:475-482.
296. Schramek D., Leibbrandt A., Sigl V., et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 2010, 468:98-102.
297. Sauvageot C.M., Weatherbee J.L., Kesari S., et al. Efficacy of the HSP90 inhibitor 17-AAG in human glioma cell lines and tumorigenic glioma stem cells. Neuro Oncol 2009, 11:109-121.
298. Folkins C., Man S., Xu P., et al. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. Cancer Res 2007, 67:3560-3564.
299. Bar E.E. Glioblastoma, cancer stem cells and hypoxia. Brain Pathol 2011, 21:119-129.
300. Qayum N., Muschel R.J., Im J.H., et al. Tumor vascular changes mediated by inhibition of oncogenic signaling. Cancer Res 2009, 69:6347-6354.
301. Brunner T.B., Geiger M., Grabenbauer G.G., et al. Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. J Clin Oncol 2008, 26:2699-2706.
302. Mesker W.E., Junggeburt J.M., Szuhai K., et al. The carcinoma-stromal ratio of colon carcinoma is an independent factor for survival compared to lymph node status and tumor stage. Cell Oncol 2007, 29:387-398.
303. West N.P., Dattani M., McShane P., et al. The proportion of tumour cells is an independent predictor for survival in colorectal cancer patients. Br J Cancer 2011, 102:1519-1523.
304. Evers P., Lee P.P., DeMarco J., et al. Irradiation of the potential cancer stem cell niches in the adult brain improves progression-free survival of patients with malignant glioma. BMC Cancer 2010, 10:384.
305. Meyer zum Büschenfelde C.M., Herrmann K., Schuster T., et al. (18)F-FDG PET-guided salvage neoadjuvant radiochemotherapy of adenocarcinoma of the esophagogastric junction: The MUNICON II trial. J Nucl Med 2011, 52:1189-1196.
306. Duprez F., De Neve W., De Gersem W., et al. Adaptive dose painting by numbers for head-and-neck cancer. Int J Radiat Oncol Biol Phys 2011, 80:1045-1055.
307. Guckenberger M., Richter A., Wilbert J., et al. Adaptive radiotherapy for locally advanced non-small-cell lung cancer does not underdose the microscopic disease and has the potential to increase tumor control. Int J Radiat Oncol Biol Phys 2011, 81:e275-e282.
308. Eisenhauer E.A., Therasse P., Bogaerts J., et al. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
309. Wahl R.L., Jacene H., Kasamon Y., et al. From RECIST to PERCIST: Evolving considerations for PET response criteria in solid tumors. J Nucl Med 2009, 50(suppl 1):122S-150S.